BACKGROUND: A pilot study was conducted to determine the safety and feasibility of intravenous administration of autologous umbilical cord blood (CB) in young children with acquired neurologic disorders. Most CB units (CBUs) were electively stored in private CB banks. Unlike public banks, which utilize specific criteria and thresholds for banking, private banks generally store all collected CBUs. STUDY DESIGN AND METHODS: CBUs of eligible patients containing more than 1 × 10⁷ cells/kg were shipped to Duke from the banks of origin after confirming identity by HLA typing. On the day of infusion, CBUs were thawed and washed in dextran-albumin and infused intravenously. Patients were medicated with acetaminophen, diphenhydramine, and methylprednisolone before transfusion. Data regarding patients, infusions, and CBUs were collected retrospectively. Characteristics of CBUs were compared to existing data from CBUs publicly banked at the Carolinas Cord Blood Bank. RESULTS: From March 2004 to December 2009, 184 children received 198 CB infusions. Three patients had infusion reactions, all responsive to medical therapy and stopping the infusion. Median precryopreservation volume (60 mL vs. 89 mL, p < 0.0001), total nucleated cell count (4.7 × 10⁸ vs. 10.8 × 10⁸, p < 0.0001), and CD34 count (1.8 × 10⁶ vs. 3.0 × 10⁶, p < 0.0001) were significantly lower than publicly stored CBUs. Postthaw sterility cultures were positive in 7.6% of infused CBUs. CONCLUSION: IV infusion of autologous CB is safe and feasible in young children with neurologic injuries. Quality parameters of privately banked CBUs are inferior to those stored in public banks. If efficacy of autologous CB is established clinically, the quality of autologous units should be held to the same standards as those stored in public banks.
BACKGROUND: A pilot study was conducted to determine the safety and feasibility of intravenous administration of autologous umbilical cord blood (CB) in young children with acquired neurologic disorders. Most CB units (CBUs) were electively stored in private CB banks. Unlike public banks, which utilize specific criteria and thresholds for banking, private banks generally store all collected CBUs. STUDY DESIGN AND METHODS: CBUs of eligible patients containing more than 1 × 10⁷ cells/kg were shipped to Duke from the banks of origin after confirming identity by HLA typing. On the day of infusion, CBUs were thawed and washed in dextran-albumin and infused intravenously. Patients were medicated with acetaminophen, diphenhydramine, and methylprednisolone before transfusion. Data regarding patients, infusions, and CBUs were collected retrospectively. Characteristics of CBUs were compared to existing data from CBUs publicly banked at the Carolinas Cord Blood Bank. RESULTS: From March 2004 to December 2009, 184 children received 198 CB infusions. Three patients had infusion reactions, all responsive to medical therapy and stopping the infusion. Median precryopreservation volume (60 mL vs. 89 mL, p < 0.0001), total nucleated cell count (4.7 × 10⁸ vs. 10.8 × 10⁸, p < 0.0001), and CD34 count (1.8 × 10⁶ vs. 3.0 × 10⁶, p < 0.0001) were significantly lower than publicly stored CBUs. Postthaw sterility cultures were positive in 7.6% of infused CBUs. CONCLUSION: IV infusion of autologous CB is safe and feasible in young children with neurologic injuries. Quality parameters of privately banked CBUs are inferior to those stored in public banks. If efficacy of autologous CB is established clinically, the quality of autologous units should be held to the same standards as those stored in public banks.
Authors: Ruth R Faden; Liza Dawson; Alison S Bateman-House; Dawn Mueller Agnew; Hilary Bok; Dan W Brock; Aravinda Chakravarti; Xiao-Jiang Gao; Mark Greene; John A Hansen; Patricia A King; Stephen J O'Brien; David H Sachs; Kathryn E Schill; Andrew Siegel; Davor Solter; Sonia M Suter; Catherine M Verfaillie; LeRoy B Walters; John D Gearhart Journal: Hastings Cent Rep Date: 2003 Nov-Dec Impact factor: 2.683
Authors: Maria L Escolar; Michele D Poe; James M Provenzale; Karen C Richards; June Allison; Susan Wood; David A Wenger; Daniel Pietryga; Donna Wall; Martin Champagne; Richard Morse; William Krivit; Joanne Kurtzberg Journal: N Engl J Med Date: 2005-05-19 Impact factor: 91.245
Authors: H E Broxmeyer; G W Douglas; G Hangoc; S Cooper; J Bard; D English; M Arny; L Thomas; E A Boyse Journal: Proc Natl Acad Sci U S A Date: 1989-05 Impact factor: 11.205
Authors: P Rubinstein; L Dobrila; R E Rosenfield; J W Adamson; G Migliaccio; A R Migliaccio; P E Taylor; C E Stevens Journal: Proc Natl Acad Sci U S A Date: 1995-10-24 Impact factor: 11.205
Authors: Martina Vendrame; Jordan Cassady; Jennifer Newcomb; Tanya Butler; Keith R Pennypacker; Tanja Zigova; Cyndy Davis Sanberg; Paul R Sanberg; Alison E Willing Journal: Stroke Date: 2004-08-19 Impact factor: 7.914
Authors: A E Willing; J Lixian; M Milliken; S Poulos; T Zigova; S Song; C Hart; J Sanchez-Ramos; P R Sanberg Journal: J Neurosci Res Date: 2003-08-01 Impact factor: 4.164
Authors: Dunyue Lu; Paul R Sanberg; Asim Mahmood; Yi Li; Lei Wang; Juan Sanchez-Ramos; Michael Chopp Journal: Cell Transplant Date: 2002 Impact factor: 4.064
Authors: Hal E Broxmeyer; Edward F Srour; Giao Hangoc; Scott Cooper; Stacie A Anderson; David M Bodine Journal: Proc Natl Acad Sci U S A Date: 2003-01-07 Impact factor: 11.205
Authors: C Michael Cotten; Amy P Murtha; Ronald N Goldberg; Chad A Grotegut; P Brian Smith; Ricki F Goldstein; Kimberley A Fisher; Kathryn E Gustafson; Barbara Waters-Pick; Geeta K Swamy; Benjamin Rattray; Siddhartha Tan; Joanne Kurtzberg Journal: J Pediatr Date: 2013-12-31 Impact factor: 4.406
Authors: Priya F Maillacheruvu; Lauren M Engel; Isaiah T Crum; Devendra K Agrawal; Eric S Peeples Journal: Pediatr Res Date: 2017-11-01 Impact factor: 3.756
Authors: Jessica M Sun; Gerald A Grant; Colleen McLaughlin; June Allison; Anne Fitzgerald; Barbara Waters-Pick; Joanne Kurtzberg Journal: Pediatr Res Date: 2015-09-02 Impact factor: 3.756